Announcement • Jun 30
Shanghai Titan Scientific Co., Ltd. to Report First Half, 2026 Results on Aug 29, 2026 Shanghai Titan Scientific Co., Ltd. announced that they will report first half, 2026 results on Aug 29, 2026 New Risk • May 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 46% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.3% average weekly change). Reported Earnings • May 01
First quarter 2026 earnings released: CN¥0.20 loss per share (vs CN¥0.03 profit in 1Q 2025) First quarter 2026 results: CN¥0.20 loss per share (down from CN¥0.03 profit in 1Q 2025). Revenue: CN¥582.9m (down 3.5% from 1Q 2025). Net loss: CN¥32.4m (down CN¥37.5m from profit in 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 77 percentage points per year, which is a significant difference in performance. Announcement • Apr 30
Shanghai Titan Scientific Co., Ltd., Annual General Meeting, May 26, 2026 Shanghai Titan Scientific Co., Ltd., Annual General Meeting, May 26, 2026, at 14:00 China Standard Time. Location: No. 258, Fengke Road, Lane 3111, Huancheng West Road, Fengxian District, Shanghai China Announcement • Mar 30
Shanghai Titan Scientific Co., Ltd. to Report Q1, 2026 Results on Apr 30, 2026 Shanghai Titan Scientific Co., Ltd. announced that they will report Q1, 2026 results on Apr 30, 2026 New Risk • Mar 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 38% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.0% average weekly change). New Risk • Mar 09
New major risk - Revenue and earnings growth Earnings have declined by 38% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company. Reported Earnings • Mar 05
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: CN¥0.08 loss per share (down from CN¥0.08 profit in FY 2024). Revenue: CN¥2.51b (down 13% from FY 2024). Net loss: CN¥13.0m (down 201% from profit in FY 2024). Revenue missed analyst estimates by 19%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 60 percentage points per year, which is a significant difference in performance. Announcement • Dec 26
Shanghai Titan Scientific Co., Ltd. to Report Fiscal Year 2025 Results on Apr 30, 2026 Shanghai Titan Scientific Co., Ltd. announced that they will report fiscal year 2025 results on Apr 30, 2026 Reported Earnings • Oct 31
Third quarter 2025 earnings released: EPS: CN¥0.009 (vs CN¥0.032 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.009 (down from CN¥0.032 in 3Q 2024). Revenue: CN¥628.9m (down 14% from 3Q 2024). Net income: CN¥1.40m (down 70% from 3Q 2024). Profit margin: 0.2% (down from 0.6% in 3Q 2024). Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 49 percentage points per year, which is a significant difference in performance. Announcement • Sep 30
Shanghai Titan Scientific Co., Ltd. to Report Q3, 2025 Results on Oct 31, 2025 Shanghai Titan Scientific Co., Ltd. announced that they will report Q3, 2025 results on Oct 31, 2025 Announcement • Jul 24
Shanghai Titan Scientific Co., Ltd. (SHSE:688133) signed a letter of intent to acquire Apollo Scientific Ltd from Central Glass Co., Ltd. (TSE:4044) for £5.7 million. Shanghai Titan Scientific Co., Ltd. (SHSE:688133) signed a letter of intent to acquire Apollo Scientific Ltd from Central Glass Co., Ltd. (TSE:4044) for £5.7 million on July 22, 2025. As on July 23, 2025, the parties entered into definitive agreement. A cash consideration will be paid by Shanghai Titan Scientific Co., Ltd.
Apollo Scientific Ltd reported Total revenue of £9.5 million, Total assets worth £13 million, Operating Loss of 0.76 million, Net Income of £0.42 million and Total Common equity of £11.8 million.
The expected completion of the transaction is October 1, 2025 to October 31, 2025. Announcement • Jun 30
Shanghai Titan Scientific Co., Ltd. to Report First Half, 2025 Results on Aug 29, 2025 Shanghai Titan Scientific Co., Ltd. announced that they will report first half, 2025 results on Aug 29, 2025 Announcement • May 22
Shanghai Titan Scientific Co., Ltd. announced a financing transaction Shanghai Titan Scientific Co., Ltd. announced a private placement on May 21, 2025. The transaction has been approved in 2024 Annual General Meeting of Shareholders. Major Estimate Revision • May 14
Consensus EPS estimates fall by 41% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from CN¥3.52b to CN¥3.32b. EPS estimate also fell from CN¥0.48 per share to CN¥0.285 per share. Net income forecast to grow 350% next year vs 42% growth forecast for Chemicals industry in China. Consensus price target up from CN¥25.50 to CN¥26.50. Share price fell 5.2% to CN¥22.62 over the past week. Announcement • Apr 25
Shanghai Titan Scientific Co., Ltd., Annual General Meeting, May 20, 2025 Shanghai Titan Scientific Co., Ltd., Annual General Meeting, May 20, 2025, at 14:00 China Standard Time. Location: No. 89, Shilong Road, Xuhui District, Shanghai China New Risk • Apr 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Profit margins are more than 30% lower than last year (0.4% net profit margin). Announcement • Mar 28
Shanghai Titan Scientific Co., Ltd. to Report Q1, 2025 Results on Apr 30, 2025 Shanghai Titan Scientific Co., Ltd. announced that they will report Q1, 2025 results on Apr 30, 2025 Reported Earnings • Mar 02
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: EPS: CN¥0.08 (down from CN¥0.44 in FY 2023). Revenue: CN¥2.88b (up 4.1% from FY 2023). Net income: CN¥12.9m (down 82% from FY 2023). Profit margin: 0.4% (down from 2.6% in FY 2023). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 6.6%. Earnings per share (EPS) also missed analyst estimates by 87%. Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 35% per year, which means it has not declined as severely as earnings. Announcement • Dec 27
Shanghai Titan Scientific Co., Ltd. to Report Fiscal Year 2024 Results on Apr 25, 2025 Shanghai Titan Scientific Co., Ltd. announced that they will report fiscal year 2024 results on Apr 25, 2025 Reported Earnings • Oct 31
Third quarter 2024 earnings released: EPS: CN¥0.032 (vs CN¥0.13 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.032 (down from CN¥0.13 in 3Q 2023). Revenue: CN¥729.1m (flat on 3Q 2023). Net income: CN¥4.61m (down 79% from 3Q 2023). Profit margin: 0.6% (down from 3.0% in 3Q 2023). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has only fallen by 41% per year, which means it has not declined as severely as earnings. Announcement • Sep 30
Shanghai Titan Scientific Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024 Shanghai Titan Scientific Co., Ltd. announced that they will report Q3, 2024 results on Oct 31, 2024 New Risk • Sep 27
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (22% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Profit margins are more than 30% lower than last year (1.0% net profit margin). Announcement • Jun 28
Shanghai Titan Scientific Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024 Shanghai Titan Scientific Co., Ltd. announced that they will report first half, 2024 results on Aug 30, 2024 Major Estimate Revision • May 06
Consensus EPS estimates fall by 10% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CN¥3.66b to CN¥3.30b. EPS estimate also fell from CN¥1.06 per share to CN¥0.95 per share. Net income forecast to grow 198% next year vs 56% growth forecast for Chemicals industry in China. Consensus price target down from CN¥47.37 to CN¥36.87. Share price fell 4.3% to CN¥28.81 over the past week. Reported Earnings • May 01
First quarter 2024 earnings released: EPS: CN¥0.02 (vs CN¥0.21 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.02 (down from CN¥0.21 in 1Q 2023). Revenue: CN¥664.2m (up 1.4% from 1Q 2023). Net income: CN¥2.31m (down 91% from 1Q 2023). Profit margin: 0.3% (down from 3.8% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 33% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 23% per year but the company’s share price has fallen by 39% per year, which means it is performing significantly worse than earnings. Announcement • May 01
Shanghai Titan Scientific Co., Ltd., Annual General Meeting, May 22, 2024 Shanghai Titan Scientific Co., Ltd., Annual General Meeting, May 22, 2024, at 14:00 China Standard Time. Location: No. 89, Shilong Road, Xuhui District, Shanghai China Valuation Update With 7 Day Price Move • Apr 16
Investor sentiment deteriorates as stock falls 20% After last week's 20% share price decline to CN¥25.00, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 15x in the Chemicals industry in China. Total loss to shareholders of 79% over the past three years. Announcement • Mar 30
Shanghai Titan Scientific Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024 Shanghai Titan Scientific Co., Ltd. announced that they will report Q1, 2024 results on Apr 30, 2024 Valuation Update With 7 Day Price Move • Mar 27
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to CN¥29.69, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 15x in the Chemicals industry in China. Total loss to shareholders of 70% over the past three years. Major Estimate Revision • Mar 03
Consensus EPS estimates fall by 53% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CN¥3.90b to CN¥3.66b. EPS estimate also fell from CN¥2.23 per share to CN¥1.06 per share. Net income forecast to grow 72% next year vs 59% growth forecast for Chemicals industry in China. Consensus price target down from CN¥68.36 to CN¥59.36. Share price was steady at CN¥33.92 over the past week. Price Target Changed • Mar 01
Price target decreased by 13% to CN¥59.36 Down from CN¥68.36, the current price target is an average from 3 analysts. New target price is 75% above last closing price of CN¥33.92. Stock is down 64% over the past year. The company is forecast to post earnings per share of CN¥2.22 for next year compared to CN¥0.62 last year. Reported Earnings • Feb 27
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: EPS: CN¥0.62 (down from CN¥1.13 in FY 2022). Revenue: CN¥2.77b (up 6.3% from FY 2022). Net income: CN¥72.8m (down 42% from FY 2022). Profit margin: 2.6% (down from 4.8% in FY 2022). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 9.1%. Earnings per share (EPS) also missed analyst estimates by 60%. Revenue is forecast to grow 33% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 27% per year, which means it is performing significantly worse than earnings. Valuation Update With 7 Day Price Move • Feb 05
Investor sentiment deteriorates as stock falls 24% After last week's 24% share price decline to CN¥26.16, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 12x in the Chemicals industry in China. Total loss to shareholders of 73% over the past three years. New Risk • Jan 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (22% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (6.0% average weekly change). Profit margins are more than 30% lower than last year (3.7% net profit margin). Valuation Update With 7 Day Price Move • Jan 22
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥34.80, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 15x in the Chemicals industry in China. Total loss to shareholders of 60% over the past three years. Reported Earnings • Nov 01
Third quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.51 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.18 (down from CN¥0.51 in 3Q 2022). Revenue: CN¥725.6m (down 5.3% from 3Q 2022). Net income: CN¥21.4m (down 62% from 3Q 2022). Profit margin: 3.0% (down from 7.3% in 3Q 2022). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 4% per year whereas the company’s share price has remained flat. New Risk • Sep 04
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 22% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. This is currently the only risk that has been identified for the company. Reported Earnings • Aug 30
Second quarter 2023 earnings released: EPS: CN¥0.50 (vs CN¥0.20 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.50 (up from CN¥0.20 in 2Q 2022). Revenue: CN¥672.9m (up 13% from 2Q 2022). Net income: CN¥25.4m (up 20% from 2Q 2022). Profit margin: 3.8% (up from 3.5% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. New Risk • Jul 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (23% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Shareholders have been diluted in the past year (10% increase in shares outstanding). Valuation Update With 7 Day Price Move • Jul 06
Investor sentiment deteriorates as stock falls 27% After last week's 27% share price decline to CN¥63.64, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 16x in the Chemicals industry in China. Total loss to shareholders of 64% over the past year. Announcement • Jun 28
Shanghai Titan Scientific Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023 Shanghai Titan Scientific Co., Ltd. announced that they will report first half, 2023 results on Aug 30, 2023 Reported Earnings • Apr 28
First quarter 2023 earnings released: EPS: CN¥0.30 (vs CN¥0.25 in 1Q 2022) First quarter 2023 results: EPS: CN¥0.30 (up from CN¥0.25 in 1Q 2022). Revenue: CN¥655.3m (up 13% from 1Q 2022). Net income: CN¥25.1m (up 29% from 1Q 2022). Profit margin: 3.8% (up from 3.3% in 1Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 35% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China. Reported Earnings • Mar 01
Full year 2022 earnings: EPS and revenues miss analyst expectations Full year 2022 results: EPS: CN¥1.60 (down from CN¥1.89 in FY 2021). Revenue: CN¥2.63b (up 22% from FY 2021). Net income: CN¥126.2m (down 12% from FY 2021). Profit margin: 4.8% (down from 6.7% in FY 2021). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 9.1%. Earnings per share (EPS) also missed analyst estimates by 27%. Revenue is forecast to grow 33% p.a. on average during the next 2 years, compared to a 19% growth forecast for the Chemicals industry in China. Price Target Changed • Jan 03
Price target decreased to CN¥181 Down from CN¥202, the current price target is an average from 2 analysts. New target price is 31% above last closing price of CN¥139. Stock is down 35% over the past year. The company is forecast to post earnings per share of CN¥2.31 for next year compared to CN¥1.89 last year. Board Change • Nov 16
Less than half of directors are independent There is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 4 experienced directors. 4 highly experienced directors. 2 independent directors (6 non-independent directors). Deputy GM & Director Hua Zhang was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Oct 28
Third quarter 2022 earnings released: EPS: CN¥0.71 (vs CN¥0.53 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.71 (up from CN¥0.53 in 3Q 2021). Revenue: CN¥765.9m (up 32% from 3Q 2021). Net income: CN¥56.0m (up 38% from 3Q 2021). Profit margin: 7.3% (up from 7.0% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Valuation Update With 7 Day Price Move • Sep 21
Investor sentiment deteriorated over the past week After last week's 20% share price decline to CN¥124, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 15x in the Chemicals industry in China. Total loss to shareholders of 46% over the past year. Reported Earnings • Aug 26
Second quarter 2022 earnings released: EPS: CN¥0.28 (vs CN¥0.40 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.28 (down from CN¥0.40 in 2Q 2021). Revenue: CN¥597.6m (up 17% from 2Q 2021). Net income: CN¥21.1m (down 30% from 2Q 2021). Profit margin: 3.5% (down from 5.9% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 50%, compared to a 42% growth forecast for the Chemicals industry in China. Reported Earnings • Apr 28
First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2022 results: EPS: CN¥0.25 (up from CN¥0.20 in 1Q 2021). Revenue: CN¥581.6m (up 42% from 1Q 2021). Net income: CN¥19.4m (up 26% from 1Q 2021). Profit margin: 3.3% (down from 3.8% in 1Q 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 8.2%. Earnings per share (EPS) missed analyst estimates by 4.1%. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Apr 19
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥144, the stock trades at a trailing P/E ratio of 73.5x. Average trailing P/E is 27x in the Chemicals industry in China. Total loss to shareholders of 12% over the past year. Valuation Update With 7 Day Price Move • Mar 09
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CN¥136, the stock trades at a forward P/E ratio of 45x. Average forward P/E is 18x in the Chemicals industry in China. Negligible returns to shareholders over past year. Reported Earnings • Feb 27
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2021 results: EPS: CN¥1.95 (up from CN¥1.70 in FY 2020). Revenue: CN¥2.18b (up 58% from FY 2020). Net income: CN¥149.0m (up 45% from FY 2020). Profit margin: 6.8% (down from 7.4% in FY 2020). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 9.1%. Earnings per share (EPS) missed analyst estimates by 1.0%. Over the next year, revenue is forecast to grow 25%, compared to a 47% growth forecast for the industry in China. Reported Earnings • Oct 28
Third quarter 2021 earnings released: EPS CN¥0.53 (vs CN¥0.53 in 3Q 2020) The company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: CN¥580.0m (up 51% from 3Q 2020). Net income: CN¥40.5m (up 33% from 3Q 2020). Profit margin: 7.0% (down from 7.9% in 3Q 2020). The decrease in margin was driven by higher expenses. Reported Earnings • Aug 26
Second quarter 2021 earnings released: EPS CN¥0.40 (vs CN¥0.31 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥513.0m (up 62% from 2Q 2020). Net income: CN¥30.2m (up 73% from 2Q 2020). Profit margin: 5.9% (up from 5.5% in 2Q 2020). The increase in margin was driven by higher revenue. Reported Earnings • Apr 29
First quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.05 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥409.9m (up 103% from 1Q 2020). Net income: CN¥15.5m (up 439% from 1Q 2020). Profit margin: 3.8% (up from 1.4% in 1Q 2020). The increase in margin was driven by higher revenue. Is New 90 Day High Low • Feb 10
New 90-day high: CN¥152 The company is up 88% from its price of CN¥80.99 on 12 November 2020. The Chinese market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 21% over the same period. Valuation Update With 7 Day Price Move • Jan 07
Investor sentiment deteriorated over the past week After last week's 18% share price decline to CN¥110, the stock is trading at a trailing P/E ratio of 76.9x, down from the previous P/E ratio of 93.2x. This compares to an average P/E of 36x in the Chemicals industry in China. Valuation Update With 7 Day Price Move • Nov 14
Market bids up stock over the past week After last week's 25% share price gain to CN¥97.19, the stock is trading at a trailing P/E ratio of 67.7x, up from the previous P/E ratio of 54.4x. This compares to an average P/E of 41x in the Professional Services industry in China. Valuation Update With 7 Day Price Move • Nov 07
Market bids up stock over the past week After last week's 18% share price gain to CN¥78.01, the stock is trading at a trailing P/E ratio of 54.4x, up from the previous P/E ratio of 46x. This compares to an average P/E of 41x in the Professional Services industry in China. Reported Earnings • Nov 04
Third quarter 2020 earnings released: EPS CN¥0.53 The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: CN¥385.2m (up 40% from 3Q 2019). Net income: CN¥30.4m (up 63% from 3Q 2019). Profit margin: 7.9% (up from 6.8% in 3Q 2019). The increase in margin was driven by higher revenue.